Hammersmith Prognostic Score as a predictor of cytogenetic and molecular response to second-line therapy in chronic myeloid leukemia
Medicinska istrazivanja · 2026 · (00) · 24-24
DOI: 10.5937/medi0-59536 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medicinska istrazivanja, 2026. Verfasst von Danijela Leković und 9 weiteren Autor:innen. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Introduction
Following failure or loss of response to imatinib in patients with chronic myeloid leukemia, selecting optimal second-line therapy and predicting treatment response are clinically important. This study aimed to evaluate the Hammersmith prognostic score as a predictor of cytogenetic and molecular response during second-line nilotinib treatment.
Methods
This retrospective study included 89 patients with chronic-phase chronic myeloid leukemia who experienced treatment failure or loss of response during standard-dose imatinib therapy. In the second-line setting, 34 patients received escalated-dose imatinib at 800 mg daily, while 55 received nilotinib at 800 mg daily. Clinical and laboratory parameters, cytogenetic and molecular responses, prognostic scores, adverse events, and survival outcomes were analyzed.
Results
Primary imatinib failure occurred in 35/89 patients (39%), while secondary failure was recorded in 54/89 patients (61%). Complete cytogenetic response during second-line therapy was achieved in 76.5% of patients receiving escalated-dose imatinib and 76.4% of those receiving nilotinib. In the nilotinib group, complete cytogenetic response was associated with higher hemoglobin levels, lower leukocyte counts and lactate dehydrogenase levels, and less pronounced hepatosplenomegaly. The Hammersmith score was the most significant independent predictor of cytogenetic and molecular response to nilotinib (HR 2.977; 95% CI 1.061-8.353; p=0.038).
Conclusion
The Hammersmith prognostic score is a simple, clinically useful tool for identifying patients more likely to achieve complete cytogenetic and molecular responses to second-line nilotinib after imatinib failure.
Zitieren
APA
Leković, D., Arsenović, I., Tanović, I., Jovanović, J., Đorđević, V., Lemajić, N., Kojić, A., Hadživuković, A., Smiljanić, M., & Bogdanović, A. (2026). Hammersmith Prognostic Score as a predictor of cytogenetic and molecular response to second-line therapy in chronic myeloid leukemia. Medicinska istrazivanja, 24-24. https://doi.org/10.5937/medi0-59536
Vancouver
Leković D, Arsenović I, Tanović I, Jovanović J, Đorđević V, Lemajić N, et al. Hammersmith Prognostic Score as a predictor of cytogenetic and molecular response to second-line therapy in chronic myeloid leukemia. Medicinska istrazivanja. 2026:24-24. doi:10.5937/medi0-59536
BibTeX
@article{Lekovi2026,
author = {Leković, Danijela and Arsenović, Isidora and Tanović, Igor and Jovanović, Jelica and Đorđević, Vesna and Lemajić, Nikola and Kojić, Andrijana and Hadživuković, Anđela and Smiljanić, Mihailo and Bogdanović, Andrija},
title = {Hammersmith Prognostic Score as a predictor of cytogenetic and molecular response to second-line therapy in chronic myeloid leukemia},
journal = {Medicinska istrazivanja},
year = {2026},
number = {00},
pages = {24--24},
doi = {10.5937/medi0-59536}
}
EUVIMED